Tech Company Financing Transactions
Visus Therapeutics Funding Round
Visus Therapeutics, operating out of Seattle, scored $36 million from Johnson & Johnson Development Corporation, RTW Investments and private investors.
Transaction Overview
Company Name
Announced On
3/10/2021
Transaction Type
Venture Equity
Amount
$36,000,000
Round
Series A
Proceeds Purpose
The company intends to use the funds to advance the clinical development program for its lead asset, BRIMOCHOL.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2 Nickerson St. 101
Seattle, WA 98109
USA
Seattle, WA 98109
USA
Phone
Website
Email Address
Not Recorded
Overview
Visus Therapeutics is a clinical-stage company developing innovative medicines to improve vision for people around the world. Visus Therapeutics has assembled a team of renowned leaders with vast eye care experience, united by the common goal of advancing drug discovery to benefit the patients we serve.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Benjamin Bergo
Chief Financial Officer
David Toll
Chief Medical Officer
Rhett Schiffman
Chief Operating Officer
Timothy Grinstead
Controller
Lee Merrill
Vice President
Patrick Hughes
Vice President
Alex Oh
VP - Human Resources
Esther Cuno
VP - Marketing
Carey Powers
VP - Operations
Cam Dang
VP - Operations
Lisa Simpson
VP - Operations
Zohra Womack
VP - R & D
James Burke
Browse more venture capital transactions:
Prev: 3/10/2021: ActZero venture capital transaction
Next: 3/10/2021: Cube venture capital transaction
Share this article
Where The Data Comes From
We do our best to document funding rounds that are announced publicly. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs